GlassScriptPhysician profile
Lauren Kritzer
NPI 1962150797
$3,808.14
in general payments reported to CMS, 2019-2025
28 companies · $1,794 in 2025
The $1,794 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $184 · 2023: $217 · 2024: $1,613 · 2025: $1,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,564 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,564.14 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.95 | 2023-2025 | |
| Novo Nordisk INC | $475.61 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $400.53 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $344.57 | 2024-2025 | Veozah |
| Lilly USA, LLC | $341.37 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $320.97 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $192.04 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.13 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $136.76 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $127.49 | 2024-2025 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $116.78 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $100.56 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Organon LLC | $87.76 | 2022-2023 | Nexplanon |
| Viiv Healthcare Company | $80.06 | 2024-2025 | Apretude |
| Azurity Pharmaceuticals, INC. | $76.04 | 2024-2025 | Edarbyclor, Horizant |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.80 | 2024-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $54.39 | 2025 | Voquezna |
| Tolmar, INC. | $25.47 | 2025 | Jatenzo |
| Sanofi-Aventis U.S. LLC | $25.25 | 2025 | |
| Axsome Therapeutics, INC. | $21.69 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.43 | 2025 | Caplyta |
| Amneal Pharmaceuticals LLC | $20.97 | 2025 | Unithroid |
| Seqirus USA INC | $17.78 | 2024 | Flucelvax, Fluad |
| Takeda Pharmaceuticals U.S.A., INC. | $16.57 | 2024 | Trintellix |
| Merck Sharp & Dohme LLC | $16.05 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $15.37 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $14.50 | 2025 | |
| Inspire Medical Systems, INC. | $14.25 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Kritzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.